Long-term real-world outcomes of first-line immunotherapy in non-small cell lung cancer - a population-based cohort study in Sweden.

Acta Oncol · 2025 · PMC11931854 · PMID 40094477

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

In a previous study, we reported an increasing trend in the use of first-line programmed death receptor-1/programmed death-ligand 1 (PD-(L)1) inhibitor-based regimens for patients with advanced NSCLC from 2017 to 2020 [ 5 ].

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.